Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.
Studies in multiple pre-clinical models of cancer have demonstrated the ability of Patrys’ proprietary humanized antibody, PAT-DX1 to be taken-up and to kill cancer cells.
This confirms the successful humanization and de-immunization of 3E10-derived antibody fragments with conserved structural properties and enhanced in vitro activity.
Company Name · Code · Last · Change · Volume
Maximus Resources Ltd · MXR · $0.002 · 100% · 653,760
Patrys Ltd · PAB · $0.007 · 75% · 27,240,497
Emperor Range Group Ltd · ERX · $0.060 · 71.43% · 8,400
Bass Oil Ltd · BAS · $0.003 · 50% · 1,200,000
Pancontinental Oil & Gas NL · PCL · $0.004 · 33.33% · 148,097,873
Shareroot Ltd · SRO · $0.009 · 28.57% · 10,354,000
Strandline Resources Ltd · STA · $0.005 · 25% · 400,000
UUV Aquabotix Ltd · UUV · $0.120 · 25% · 269,478
Chapmans Ltd · CHP · $0.005 · 25% · 650,000
NTM Gold Ltd · NTM · $0.055 · 22.22% · 33,800